As shown in Figure 3B, the ranking probabilities of treatment from the network meta-analysis of OS indicated that, of the 6 therapeutic strategies, combined BRAF-MEK inhibition had the highest probability of being the best treatment arm for MM. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.